Company intelligence / Profile preview
HERVolution Therapeutics
Frederiksberg (Copenhagen), Hovedstaden, Denmark
- Ownership
- Private
- Employees
- ~11
- Development stage
- Other
01
Overview
Robust preclinical data demonstrate immune cell activation towards HERVs; lead dual-vector adenovirus candidate IPT-001 targets HERVs in oncology and aging, with IND-enabling studies ongoing and first clinical trials planned for 2025.[3][5][6]
- Therapeutic areas
- EndocrinologyMetabolic DisordersOtherOncologyNeurology
- Modalities
- Therapeutic vaccineRecombinant vector vaccineBiologic
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Serum Institute of India
Beyond the preview
Go deeper on HERVolution Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HERVolution Therapeutics.